Latest news about Concord Drugs
Concord Drugs
79.68
0.00(0.00%)
Company Performance:
View Company Insights1D0.00%
1M+11.89%
6M+7.39%
1Y+18.36%
5Y+202.97%
More news about Concord Drugs
01Jun 26
Concord Drugs FY26 profit surges 215% to ₹105.50 lakh
Concord Drugs Limited reported a consolidated net profit of ₹105.50 lakh for FY26, a 215% increase from the previous year, driven by a 74% surge in revenue to ₹7,877.13 lakh. The Board approved the results on May 27, 2026. The auditors noted outstanding trade receivables of ₹4.14 crore without provision for bad debts.
11Apr 26
Concord Drugs submits quarterly certificate under SEBI Depositories Regulations
Concord Drugs Limited has submitted its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The certificate, issued by R&T Agent Aarthi Consultants Private Limited, confirms adherence to dematerialization requirements and proper handling of securities transactions during the quarter.
17Feb 26
Concord Drugs Limited Reports 56.5% Revenue Growth in Q3FY26
Concord Drugs Limited reported strong Q3FY26 financial results with revenue growth of 56.5% to ₹1,686.13 lakhs compared to ₹1,077.39 lakhs in Q3FY25. Net profit for the quarter was ₹21.52 lakhs, while nine-month revenue reached ₹4,032.00 lakhs with net profit of ₹52.06 lakhs. The Board approved these results on February 14, 2026.
16Feb 26
Concord Drugs Issues Corrigendum on Q3FY26 Results for Labour Codes Disclosure
Concord Drugs Limited submitted its Q3FY26 auditor's review report and subsequently issued a corrigendum addressing Labour Codes implementation details. The company's subsidiary Proton Remedies reported revenue of ₹124.83 lakhs and net profit of ₹1.17 lakhs for nine months, while the company raised ₹13,36,29,375 through preferential issues in November 2025.
30Dec 25
Concord Drugs Limited Secures Purchase Orders Worth ₹14.71 Crores from Government Entities
Concord Drugs Limited has secured purchase orders worth ₹14.71 crores from government entities including TNMSC, DGHS, and TGMSIDC for pharmaceutical products supply. The orders are to be executed within 45-60 days and are expected to positively impact the company's business operations. All transactions are domestic and comply with regulatory requirements.
24Nov 25
Concord Drugs Promoters Boost Holdings Through Preferential Allotment
Concord Drugs Limited's promoters and directors have increased their stakes through a preferential allotment on November 20, 2025. Nagi Reddy, Koni Reddy, and Manoj Kumar Reddy, all promoters and directors, acquired both equity shares and warrants. The company has disclosed these transactions in compliance with SEBI regulations on insider trading.
20Nov 25
Concord Drugs Limited Raises ₹18.88 Crore Through Preferential Allotment
Concord Drugs Limited (CDL) completed a capital raising initiative through a preferential allotment of equity shares and convertible warrants. The company allotted 31,75,000 equity shares at ₹36.30 per share, raising ₹11.53 crore. Additionally, 20,25,000 convertible warrants were issued at ₹36.30 each, potentially raising ₹7.35 crore. The allotment was made to both promoters and public investors, with promoters receiving 5,00,000 equity shares and 18,00,000 warrants, while the public received 26,75,000 shares and 2,25,000 warrants. The warrants are convertible within 18 months, subject to payment of the balance consideration.
14Nov 25
Concord Drugs Reports Mixed Financial Performance for Q2 FY2026
Concord Drugs Limited announced its H1 FY2026 results, showing slight improvements in revenue and profitability. Consolidated net sales reached Rs 2,388.25 crore, with a profit after tax of Rs 31.00 crore. The company's total assets increased to Rs 6,861.30 crore, and total equity rose to Rs 3,441.89 crore. Both standalone and consolidated earnings per share remained at Rs 0.31.
08Aug 25
Concord Drugs Reports 31% Revenue Growth and Quadrupled Profit in Q1
Concord Drugs Limited reported robust Q1 financial results. Consolidated revenue reached Rs 1,360.64 crore, up 31% quarter-on-quarter and 16.4% year-on-year. Net profit surged to Rs 11.77 crore, a threefold increase from the previous quarter and more than fourfold from the same period last year. Standalone revenue was Rs 1,338.35 crore with Rs 11.14 crore net profit. The company's subsidiary, Proton Remedies Private Limited, contributed Rs 40.44 crore to revenue and Rs 0.62 crore to profit. Basic EPS improved to Rs 0.12, and the company reported no loan defaults.
30Jun 25
Concord Drugs to Hold Board Meeting on Fundraising Initiatives
Concord Drugs Ltd has announced a board meeting on July 3 to discuss fundraising and capital raising initiatives. The meeting signals the company's active consideration of strategies to strengthen its financial position, which could potentially support various aspects of operations such as research and development, facility expansion, market growth, debt reduction, or working capital requirements.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Zydus Life Science
Cipla
Laurus Labs
Aurobindo Pharma
Lupin
Dr Reddys Laboratories
Mankind Pharma
1,864.90
(-1.11%)
9,488.00
(-0.91%)
4,930.00
(-0.60%)
1,127.40
(-1.58%)
1,363.10
(-1.51%)
1,937.00
(-0.51%)
1,698.90
(+0.41%)
2,100.00
(-0.22%)
1,145.00
(-0.52%)
2,265.00
(-1.91%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
